Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)

BACKGROUND: Fibroblast growth factor 23 (FGF23) is associated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease, and calcimimetic therapy reduces plasma concentrations of FGF23. It remains unknown whether treatment with the calcimimetic etelcalcetide (ETL) reduces LVH i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörr, Katharina, Kammer, Michael, Reindl-Schwaighofer, Roman, Lorenz, Matthias, Loewe, Christian, Marculescu, Rodrig, Erben, Reinhold, Oberbauer, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813957/
https://www.ncbi.nlm.nih.gov/pubmed/31651370
http://dx.doi.org/10.1186/s13063-019-3707-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813957/
https://www.ncbi.nlm.nih.gov/pubmed/31651370
http://dx.doi.org/10.1186/s13063-019-3707-7

Ejemplares similares